|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:etanercept
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:ATCCode
|
gptkb:L04AB01
|
|
gptkbp:biosimilar
|
yes
|
|
gptkbp:CASNumber
|
gptkb:185243-69-0
|
|
gptkbp:chemicalClass
|
gptkb:protein
|
|
gptkbp:contraindication
|
sepsis
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
70–100 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Enbrel
|
|
gptkbp:KEGGID
|
gptkb:D02596
|
|
gptkbp:legalStatus
|
prescription only
patent expired in US (2012)
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
gptkb:Amgen
|
|
gptkbp:mechanismOfAction
|
tumor necrosis factor inhibitor
|
|
gptkbp:MedlinePlusID
|
a601044
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescriptionRequired
|
https://www.enbrel.com/
|
|
gptkbp:PubChem_CID
|
gptkb:DB00005
16130129
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
headache
injection site reaction
increased risk of infection
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:TNF-alpha
|
|
gptkbp:UNII
|
5G06F7PR3V
|
|
gptkbp:usedFor
|
gptkb:juvenile_idiopathic_arthritis
gptkb:psoriatic_arthritis
rheumatoid arthritis
ankylosing spondylitis
plaque psoriasis
|
|
gptkbp:bfsParent
|
gptkb:Wyeth
|
|
gptkbp:bfsLayer
|
5
|